Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

@article{Hershfield2013ClinicalPI,
  title={Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.},
  author={Michael S. Hershfield and J. Thomas Callaghan and Wichittra Tassaneeyakul and Taisei Mushiroda and Caroline F. Thorn and Teri E. Klein and Ming Ta Michael Lee},
  journal={Clinical pharmacology and therapeutics},
  year={2013},
  volume={93 2},
  pages={
          153-8
        }
}
Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer… CONTINUE READING
Highly Cited
This paper has 82 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 70 citations

82 Citations

01020'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 82 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 49 references

A prospective study of HLA-B*5801 genotyping for the prevention of allopurinol induced severe cutaneous adverse reactions. American Society for Clinical Pharmacology and Therapeutics

  • M. Lee, Y. Chen, C. A. Shen
  • 113th Annual Meeting,
  • 2012

a proposed safe starting dose of allopurinol

  • Stamp, L. K. et al. Starting dose is a risk factor for allop syndrome
  • Arthritis Rheum. 64, 2529–2536
  • 2012